Novavax Initiates Pivotal Phase 3 Trial of the RSV F Vaccine in Older Adults
Go back to Novavax Initiates Pivotal Phase 3 Trial of the RSV F Vaccine in Older Adults| Novavax, Inc. (NASDAQ: NVAX) | Delayed: 10.02 -0.99 (8.99%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $11.01 | 52 Week High | $9.23 | |||
| Open | $10.79 | 52 Week Low | $1.16 | |||
| Day High | $10.87 | P/E | N/A | |||
| Day Low | $9.56 | EPS | $-0.30 | |||
| Volume | 10,471,508 | |||||



